The American Journal of Medicine
Volume 121, Issue 6 , Pages 515-518 , June 2008

Multicenter Evaluation of Vancomycin Dosing: Emphasis on Obesity

  • Ronald G. Hall II, PharmD

      Affiliations

    • Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas
    • Department of Pharmacy, North Texas Veterans Health Care System, Dallas, Texas
    • Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas
    • Corresponding Author InformationRequests for reprints should be addressed to Ronald G. Hall, PharmD, BCPS, 4500 S Lancaster, Bldg 7, Route 119A, Dallas, TX 75216.
    • ,
  • Kenna D. Payne, PharmD

      Affiliations

    • Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas
    • Department of Pharmacy, North Texas Veterans Health Care System, Dallas, Texas
    • ,
  • Amy M. Bain, PharmD

      Affiliations

    • Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas
    • Department of Pharmacy, North Texas Veterans Health Care System, Dallas, Texas
    • ,
  • Anita P. Rahman, PharmD

      Affiliations

    • Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas
    • Department of Pharmacy, North Texas Veterans Health Care System, Dallas, Texas
    • ,
  • Sean T. Nguyen, PharmD

      Affiliations

    • Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas
    • Department of Pharmacy, Presbyterian Hospital of Dallas, Texas
    • ,
  • Susan A. Eaton, PharmD

      Affiliations

    • Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas
    • Department of Pharmacy, Presbyterian Hospital of Dallas, Texas
    • ,
  • Anthony J. Busti, PharmD

      Affiliations

    • Department of Pharmacy Practice, Texas Tech University Health Sciences Center, School of Pharmacy, Dallas, Texas
    • Department of Pharmacy, North Texas Veterans Health Care System, Dallas, Texas
    • ,
  • Stephen L. Vu, MD

      Affiliations

    • Department of Internal Medicine, Presbyterian Hospital, Dallas, Texas
    • ,
  • Roger Bedimo, MD, MS

      Affiliations

    • Department of Medicine, North Texas Veterans Health Care System, Dallas, Tex
    • Department of Medicine, The University of Texas Southwestern Medical Center, Dallas, Tex.

References 

  1. Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006;295:1549–1555
  2. Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27:1081–1091
  3. Vance-Bryan K, Guay DR, Gilliland SS, et al. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother. 1993;37:436–440
  4. Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21:575–580
  5. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol. 1998;54:621–625
  6. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267–1284
  7. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373–1406
  8. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416
  9. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111:e394–e434
  10. Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003;37:1298–1303
  11. Weigelt J, Itani K, Stevens D, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49:2260–2266
  12. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25:980–992
  13. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis. 2001;32:402–412
  14. Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis. 2005;41(Suppl 5):S341–S353
  15. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665
  16. Charles PG, Ward PB, Johnson PD, et al. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38:448–451
  17. Tsuji BT, Rybak MJ, Lau KL, Sakoulas G. Evaluation of accessory gene regulator (agr) group and function in the proclivity towards vancomycin intermediate resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 2007;51:1089–1091
  18. Obesity: Preventing and Managing the Global Epidemic. Geneva: World Health Organization; 2000;(WHO Technical Report Series, No. 894)
  19. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents. 2000;16(Suppl 1):S31–S34
  20. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43:925–942
  21. Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest. 2006;130:947–955
  22. Mohr JF, Murray BE. Point: vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44:1536–1542
  23. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001 05. J Antimicrob Chemother. 2007;60:788–794

 This project was supported by Grant Number KL2RR024983, titled “North and Central Texas Clinical and Translational Science Initiative” (Milton Packer, MD, PI) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NCRR or NIH. Information on NCRR is available at http://www.ncrr.nih.gov/. Information on Re-engineering the Clinical Research Enterprise can be obtained from http://nihroadmap.nih.gov/clinicalresearch/overview-translational.asp.

PII: S0002-9343(08)00230-1

doi: 10.1016/j.amjmed.2008.01.046

The American Journal of Medicine
Volume 121, Issue 6 , Pages 515-518 , June 2008

Article Tools